The Fast Company Executive Board is a private, fee-based network of influential leaders, experts, executives, and entrepreneurs who share their insights with our audience. BY Guy Yehiav In the U.S., ...
As clinical development grows more complex, sponsors are rethinking how outsourcing models, technology, and partnerships align to support both speed and sustainability. The shift toward hybrid models, ...
The FDA has opened the door to the use of Bayesian statistical methods in clinical trials. The worry: Introducing ...
Bari Kowal, Senior Vice President, Development Operations & Portfolio Management at Regeneron Clinical trial innovation is a hot topic, but it’s not a new one. The first fully virtual randomized trial ...
Clinical development is undergoing a structural shift. Protocols are growing more complex, budgets are shrinking, and expectations from regulators, payers, and patients continue to rise. Meanwhile, ...
Diversity in clinical trials matters for drug safety and efficacy—and for future medical advancements. Clinical trial ...
TOKYO & MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and ...
Please provide your email address to receive an email when new articles are posted on . A health technology startup in the United Kingdom has developed an online platform designed to streamline the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results